Introduction: Residual or recurrent cervical cancer post-CCRT is a challenging clinical issue, even though there has been much effort in recent decades to increase patient survival after radiation. There is a paucity of literature regarding the role of hysterectomy in recurrent/residual disease after radiation in LACC patients. Such a procedure is controversial and not routinely performed because of difficulties in obtaining tumor-free margins and the high rate of associated morbidity.
Aims And Objectives: Evaluate outcomes and morbidities in patients who had undergone hysterectomy for residual or recurrent disease after radiation in LACC patients.
Material And Methods: This is a prospective observational study on radiotherapy-treated LACC patients (IIB-III) with residual disease or recurrent disease who have undergone adjuvant hysterectomy. This study has been conducted at AHPGIC, Cuttack, with a sample size of 30 patients.
Results: 18/30 patients underwent extrafascial hysterectomy, and rest 12 patients had radical hysterectomy. No significant difference in complications, achieving tumor free margins or recurrences post adjuvant hysterectomy based on the radicality of surgery was observed. 5 cases of recurrences post-adjuvant hysterectomy were detected. Some of the factors which had significant association with recurrences post adjuvant hysterectomy were non squamous histology, no preoperative brachytherapy, deep stromal invasion and positive surgical margins. Median follow-up time was 14 months (12-27 months).
Conclusion: This study shows that adjuvant hysterectomy is feasible with good outcome and acceptable morbidity after chemoradiotherapy in cervical cancer patients "
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11399492 | PMC |
http://dx.doi.org/10.1007/s13224-024-02053-w | DOI Listing |
Cureus
November 2024
Plastic and Reconstructive Surgery, Amrita Institute of Medical Sciences, Kochi, IND.
A 50-year-old woman with a history of adult granulosa cell tumor (AGCT) of the right ovary was under follow-up after undergoing several surgeries, including a total abdominal hysterectomy with bilateral salpingo-oophorectomy. She was initially diagnosed eight years ago and remained disease-free for 52 months. However, she later experienced a recurrence, indicated by elevated inhibin B levels (58 ng/mL) and the presence of peritoneal soft tissue tumors.
View Article and Find Full Text PDFJ Gynecol Oncol
December 2024
Division of Epidemiology, College of Public Health, The Ohio State University, Columbus, OH, USA.
Objective: Surgery is the mainstay of treatment for low-grade endometrial stromal sarcoma (LG-ESS). While adjuvant hormone therapy is recommended for patients with advanced/recurrent disease, no consensus regarding its use among early-stage patients exists. We aimed to identify correlates of adjuvant hormone therapy use and associations of adjuvant hormone therapy and overall survival (OS) in stage I LG-ESS patients.
View Article and Find Full Text PDFFront Med (Lausanne)
December 2024
Department of Pathology, Affiliated Dongyang Hospital of Wenzhou Medical University, Dongyang, Zhejiang, China.
Human papillomavirus (HPV)-related multiphenotypic sinonasal carcinoma (HMSC) is a biphasic epithelial tumor associated with HPV infection. This rare tumor primarily affects the nasal cavity and paranasal sinuses, with only two cases reported outside these locations to date-one in the breast and one in the vulva. This report presents a case of a tumor resembling an HMSC arising in the cervix.
View Article and Find Full Text PDFIntroduction Uterine fibroids (UFs), also known as leiomyomas, are the most common benign gynecological tumors. Currently, morcellation is discouraged owing to the risk of disseminating undetected malignancies. This study aims to update the prevalence data on occult malignancies in surgeries for suspected benign uterine lesions and analyze the impact of treatment strategies on survival outcomes in patients with occult malignancies.
View Article and Find Full Text PDFCureus
November 2024
Medical Oncology, Tata Main Hospital, Jamshedpur, IND.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!